U.S. markets closed

Imagion Biosystems Limited (IBX.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0380+0.0010 (+2.70%)
At close: 04:10PM AEST

Imagion Biosystems Limited

5601 Oberlin Drive
Suite 100
San Diego, CA 92121
United States
855 564 5264

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert Romeo ProulxExec. Chairman, Pres & CEO432.9kN/A1958
Mr. Geoff HollisCFO & Company Sec.300.17kN/AN/A
Dr. Yalia Jayalakshmi Ph.D.Chief Devel. Officer427.06kN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.

Corporate Governance

Imagion Biosystems Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.